Literature DB >> 28991249

Donor cell-derived transient abnormal myelopoiesis as a specific complication of umbilical cord blood transplantation.

N Hiramoto1, J Takeda2, K Yoshida2, Y Ono3, S Yoshioka3, N Yamauchi3, A Fujimoto3, H Maruoka4, Y Shiraishi5, H Tanaka5, K Chiba5, Y Imai6, S Miyano5, S Ogawa2, T Ishikawa3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28991249     DOI： 10.1038/bmt.2017.226

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

Review 1.  Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Vienna experience.

Authors:  E Schraml; H Daxberger; F Watzinger; T Lion
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

Review 2.  Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.

Authors:  Rintaro Ono; Daisuke Hasegawa; Shinsuke Hirabayashi; Takahiro Kamiya; Kenichi Yoshida; Satoko Yonekawa; Chitose Ogawa; Ryota Hosoya; Tsutomu Toki; Kiminori Terui; Etsuro Ito; Atsushi Manabe
Journal:  Eur J Pediatr       Date:  2014-09-30       Impact factor: 3.183

3.  The landscape of somatic mutations in Down syndrome-related myeloid disorders.

Authors:  Kenichi Yoshida; Tsutomu Toki; Yusuke Okuno; Rika Kanezaki; Yuichi Shiraishi; Aiko Sato-Otsubo; Masashi Sanada; Myoung-ja Park; Kiminori Terui; Hiromichi Suzuki; Ayana Kon; Yasunobu Nagata; Yusuke Sato; RuNan Wang; Norio Shiba; Kenichi Chiba; Hiroko Tanaka; Asahito Hama; Hideki Muramatsu; Daisuke Hasegawa; Kazuhiro Nakamura; Hirokazu Kanegane; Keiko Tsukamoto; Souichi Adachi; Kiyoshi Kawakami; Koji Kato; Ryosei Nishimura; Shai Izraeli; Yasuhide Hayashi; Satoru Miyano; Seiji Kojima; Etsuro Ito; Seishi Ogawa
Journal:  Nat Genet       Date:  2013-09-22       Impact factor: 38.330

4.  Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.

Authors:  Kazuko Kudo; Asahito Hama; Seiji Kojima; Ruriko Ishii; Akira Morimoto; Fumio Bessho; Shosuke Sunami; Naoyuki Kobayashi; Akitoshi Kinoshita; Yuri Okimoto; Akio Tawa; Ichiro Tsukimoto
Journal:  Int J Hematol       Date:  2010-03-18       Impact factor: 2.490

5.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Authors:  Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

6.  Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.

Authors:  Oliver Tunstall-Pedoe; Anindita Roy; Anastasios Karadimitris; Josu de la Fuente; Nicholas M Fisk; Phillip Bennett; Alice Norton; Paresh Vyas; Irene Roberts
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

7.  Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.

Authors:  Sergey I Nikolaev; Federico Santoni; Anne Vannier; Emilie Falconnet; Emanuela Giarin; Giuseppe Basso; Alexander Hoischen; Joris A Veltman; Jurgen Groet; Dean Nizetic; Stylianos E Antonarakis
Journal:  Blood       Date:  2013-06-03       Impact factor: 22.113

8.  A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481.

Authors:  Gita V Massey; Alvin Zipursky; Myron N Chang; John J Doyle; Suhail Nasim; Jeffrey W Taub; Yaddanapudi Ravindranath; Gary Dahl; Howard J Weinstein
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

9.  Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.

Authors:  Kazuko Kudo; Seiji Kojima; Ken Tabuchi; Hiromasa Yabe; Akio Tawa; Masue Imaizumi; Ryoji Hanada; Kazuko Hamamoto; Ryoji Kobayashi; Akira Morimoto; Hideki Nakayama; Masahiro Tsuchida; Keizo Horibe; Hisato Kigasawa; Ichiro Tsukimoto
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

10.  GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.

Authors:  Irene Roberts; Kate Alford; Georgina Hall; Gaetan Juban; Helen Richmond; Alice Norton; Grant Vallance; Kelly Perkins; Emanuele Marchi; Simon McGowan; Anindita Roy; Gillian Cowan; Mark Anthony; Amit Gupta; John Ho; Sabita Uthaya; Anna Curley; Shree Vishna Rasiah; Timothy Watts; Richard Nicholl; Alison Bedford-Russell; Raoul Blumberg; Angela Thomas; Brenda Gibson; Chris Halsey; Pek-Wan Lee; Sunit Godambe; Connor Sweeney; Neha Bhatnagar; Anne Goriely; Peter Campbell; Paresh Vyas
Journal:  Blood       Date:  2013-09-10       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.